THURSDAY, Mar. 12 (HealthDay News) -- Treating diabetic patients with reconstituted high-density lipoprotein (rHDL) reduces inflammation, increases cholesterol efflux from macrophages and may be atheroprotective, according to study findings published in the Mar. 17 issue of the Journal of the American College of Cardiology.
Sanjay Patel, from the Heart Research Institute in Sydney, Australia, and colleagues examined anti-inflammatory markers in 13 male patients with type 2 diabetes mellitus treated with 80 mg/kg rHDL and saline placebo on separate occasions at least four weeks apart in random order.
The investigators found that rHDL significantly reduced inflammation by up to 25 percent up to 72 hours post-infusion, in parallel to its plasma concentration. In addition, rHDL reduced the expression of adhesion molecules on stimulated human coronary endothelial cells, reduced the expression of an adhesion molecule on peripheral blood monocytes, reduced neutrophil adhesion to fibrinogen, and enhanced cholesterol efflux from macrophages by 40 to 60 percent, the researchers report.
"In summary, this study highlights the important and significant anti-inflammatory effects of rHDL infusions on plasma HDL in diabetic individuals, which are related to an increase in its plasma concentration and persist even up to 72 hours post-infusion," Patel and colleagues conclude. "Thus infusions of rHDL may not only have therapeutic utility in reducing atheroma burden, but may also be used to suppress the widespread vascular inflammation that characterizes the acute coronary and cerebrovascular syndromes."
Reconstituted HDL was supplied by CSL Behring AG in Bern, Switzerland.